Expert Interview
Analyzing the Phase 3 THRIVE-2 Trial Results for Veligrotug in Chronic Thyroid Eye Disease from Viridian Therapeutics (VRDN)
Ticker(s): VRDNAn ophthalmologist or endocrinologist with expertise in thyroid eye disease, particularly in clinical research settings. The expert should have experience in evaluating treatments for TED and an understanding of the role of IGF-1R inhibitors in managing this complex autoimmune condition.
The THRIVE-2 trial reported a 56% proptosis responder rate, with rapid onset observed as early as 3 weeks. How does this result compare to current treatment options, and what does it signify for patient outcomes in chronic TED?
Added By: slingshot_insightsWith 32% of patients achieving complete resolution of diplopia and 56% showing significant improvement, how transformative could these outcomes be for individuals living with chronic TED?
Added By: slingshot_insightsTHRIVE-2 demonstrated a significant reduction in CAS, with 54% of patients achieving near-maximal therapeutic effect (CAS ≤1). How important is CAS reduction in terms of managing inflammation and improving overall disease activity in TED?
Added By: slingshot_insightsVeligrotug was generally well-tolerated, with a 94% treatment completion rate and a low rate of adverse events. How does this safety profile influence its potential adoption as a long-term therapy for chronic TED?
Added By: slingshot_insightsPatients in the THRIVE-2 trial experienced rapid responses in both proptosis and diplopia after just a few infusions. How critical is this rapid onset for patient adherence and satisfaction compared to current treatment options?
Added By: slingshot_insightsThe placebo-adjusted rate for diplopia improvement was 31%, and for complete resolution, 18%. What do these numbers reveal about the specificity and effectiveness of veligrotug as an IGF-1R inhibitor?
Added By: slingshot_insightsViridian plans to submit a Biologics License Application (BLA) for veligrotug in the second half of 2025. What challenges and opportunities might the company face in bringing this therapy to market, given the unmet needs in TED?
Added By: slingshot_insightsWith veligrotug’s success in THRIVE-2, how might these results influence the ongoing development of subcutaneous VRDN-003, and what role could it play in the broader TED treatment landscape?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
